Pretherapeutic laboratory findings, extent of metastasis and choice of treatment as prognostic markers in ocular melanoma-a single centre experience

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 3, 2013, Pages

  Schicher, N ^a   Edelhauser, G ^b   Harmankaya, K ^a   Schindler, K ^a   Gleiss, A ^c   Pehamberger, H ^a   Hoeller, C ^a  

^a Division of General Dermatology   (Austria)

^b Division of Cardiovascular and Interventional Radiology   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; DACARBAZINE; FIBRINOGEN; FOTEMUSTINE; IPILIMUMAB; LACTATE DEHYDROGENASE; OBLIMERSEN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CLINICAL ARTICLE; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; UVEA MELANOMA;

ALBUMINS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DISEASE-FREE SURVIVAL; FEMALE; FIBRINOGEN; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RETROSPECTIVE STUDIES; UVEAL NEOPLASMS;

EID: 84874105370     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12006     Document Type: Article

References (32)

1. Singh AD, Turell ME, Topham AK,. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology [Review]. 2011; 118: 1881-1885.
2. Virgili G, Gatta G, Ciccolallo L, et al. Incidence of uveal melanoma in Europe. Ophthalmology [Research Support, Non-U.S. Gov't]. 2007; 114: 2309-2315.
3. Tucker MA, Shields JA, Hartge P, et al. Sunlight exposure as risk factor for intraocular malignant melanoma. N Engl J Med [Comparative Study Research Support, Non-U.S. Gov't]. 1985; 313: 789-792.
4. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol [Research Support, N.I.H., Extramural]. 2005; 123: 1639-1643.
5. Rietschel P, Panageas KS, Hanlon C, et al. Variates of survival in metastatic uveal melanoma. J Clin Oncol 2005; 23: 8076-8080.
6. Schuster R, Lindner M, Wacker F, et al. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome. Melanoma Res 2010; 20: 191-196.
7. Vogl T, Eichler K, Zangos S, et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol [Clinical Trial]. 2007; 133: 177-184.
8. Peters S, Voelter V, Zografos L, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 2006; 17: 578-583.
9. Mariani P, Piperno-Neumann S, Servois V, et al. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. Eur J Surg Oncol 2009; 35: 1192-1197.
10. Pons F, Plana M, Caminal JM, et al. Metastatic uveal melanoma: is there a role for conventional chemotherapy?-A single center study based on 58 patients. Melanoma Res [Review]. 2011; 21: 217-222.
11. Homsi J, Bedikian AY, Papadopoulos NE, et al. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. Melanoma Res [Clinical Trial, Phase II Research Support, Non-U.S. Gov't]. 2010; 20: 507-510.
12. Schmittel A, Schmidt-Hieber M, Martus P, et al. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol [Clinical Trial, Phase II Randomized Controlled Trial]. 2006; 17: 1826-1829.
13. Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol [Research Support, Non-U.S. Gov't]. 2009; 127: 989-998.
14. Thomas S, Putter C, Weber S, et al. Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up study. Br J Cancer [Research Support, Non-U.S. Gov't]. 2012; 13: 106.
15. Polterauer S, Seebacher V, Hefler-Frischmuth K, et al. Fibrinogen plasma levels are an independent prognostic parameter in patients with cervical cancer. Am J Obstet Gynecol 2009; 200: 647 e1-647 e7.
16. Kohli M, Fink LM, Spencer HJ, et al. Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis 2002; 13: 1-5.
17. Yamashita H, Kitayama J, Kanno N, et al. Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer. BMC Cancer 2006; 6: 147.
18. Deichmann M, Kahle B, Moser K, et al. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer 2004; 91: 699-702.
19. Augsburger JJ, Correa ZM, Trichopoulos N,. Surveillance testing for metastasis from primary uveal melanoma and effect on patient survival. Am J Ophthalmol [Research Support, Non-U.S. Gov't Review]. 2011; 152: 5-9.
20. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2009; 457: 599-602.
21. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2010; 363: 2191-2199.
22. Zuidervaart W, van Nieuwpoort F, Stark M, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer [Research Support, Non-U.S. Gov't]. 2005; 92: 2032-2038.
23. Papastefanou VP, Cohen VM,. Uveal melanoma. J Skin Cancer 2011; 2011:573974.
24. Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105: 178-185.
25. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000; 96: 3302-3309.
26. Gunji Y, Gorelik E,. Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells. Cancer Res 1988; 48: 5216-5221.
27. Cardinali M, Uchino R, Chung SI,. Interaction of fibrinogen with murine melanoma cells: covalent association with cell membranes and protection against recognition by lymphokine-activated killer cells. Cancer Res 1990; 50: 8010-8016.
28. Deichmann M, Benner A, Bock M, et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999; 17: 1891-1896.
29. Lin WW, Karin M,. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Investig [Review]. 2007; 117: 1175-1183.
30. Dunavoelgyi R, Funk M, Sacu S, et al. Intraocular activation of angiogenic and inflammatory pathways in uveal melanoma. Retina 2012; 32: 1373-1384.
31. Schuster R, Bechrakis NE, Stroux A, et al. Prognostic relevance of circulating tumor cells in metastatic uveal melanoma. Oncology 2011; 80: 57-62.
32. Diener-West M, Hawkins BS, Markowitz JA, et al. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988 Arch Ophthalmol [Meta-Analysis Research Support, U.S. Gov't, P.H.S.]. 1992; 110: 245-250.